Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
| Autor: | Adrienne Nedved, Kami Maddocks, Grzegorz S Nowakowski |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | The Oncologist. 28:199-207 |
| ISSN: | 1549-490X 1083-7159 |
| DOI: | 10.1093/oncolo/oyac256 |
| Popis: | Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 24% of new cases of B-cell non-Hodgkin lymphoma in the US each year. Up to 50% of patients relapse or are refractory (R/R) to the standard first-line treatment option, R-CHOP. The anti-CD19 monoclonal antibody tafasitamab, in combination with lenalidomide (LEN), is an NCCN preferred regimen for transplant-ineligible patients with R/R DLBCL and received accelerated approval in the US (July 2020) and conditional marketing authorization in Europe (August 2021) and other countries, based on data from the L-MIND study. The recommended dose of tafasitamab is 12 mg/kg by intravenous infusion, administered in combination with LEN 25 mg for 12 cycles, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. Tafasitamab + LEN is associated with durable responses in patients with R/R DLBCL. The majority of clinically significant treatment-associated adverse events are attributable to LEN and can be managed with dose modification and supportive therapy. We provide guidelines for the management of patients with R/R DLBCL treated with tafasitamab and LEN in routine clinical practice, including elderly patients and those with renal and hepatic impairment, and advice regarding patient education as part of a comprehensive patient engagement plan. Our recommendations include LEN administration at a reduced dose if required in patients unable to tolerate the recommended dose. No dose modification is required for tafasitamab in special patient populations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|